Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease

Riccardo Di Domenicantonio, Francesco Trotta, Silvia Cascini, Nera Agabiti, Anna Kohn, Antonio Gasbarrini, Marina Davoli, Antonio Addis

Research output: Contribution to journalArticle

Abstract

Background: The comparison of effectiveness and safety of anti-tumor necrosis factor-alpha agents for the treatment of inflammatory bowel disease (IBD) is relevant for clinical practice and stakeholders. Objective: The objective of this study was to compare the risk of abdominal surgery, steroid utilization, and hospitalization for infection in Crohn’s disease (CD) or ulcerative colitis (UC) patients newly treated with infliximab (IFX) or adalimumab (ADA). Methods: A retrospective population-based cohort study was performed using health information systems data from Lazio region, Italy. Patients with CD or UC diagnosis were enrolled at first prescription of IFX or ADA during 2008–2014 (index date). Only new drug users were followed for 2 years from the index date. IFX versus ADA adjusted hazard ratios were calculated applying “intention-to-treat” approach, controlling for several characteristics and stratifying the analysis on steroid use according to previous drug utilization. Sensitivity analyses were performed according to “as-treated” approach, adjusting for propensity score, censoring at switching or discontinuation, and evaluating different lengths of follow-up periods. Results: We enrolled 1,432 IBD patients (42% and 83% exposed to IFX for CD and UC, respectively). In both diseases, treatment effects did not differ in any outcome considered, and sensitivity analyses confirmed the results from the main analysis. Conclusion: In our population-based cohort study, effectiveness and safety data in new users of ADA or IFX with CD or UC were comparable for the outcomes we tested.

Original languageEnglish
Pages (from-to)203-213
Number of pages11
JournalClinical Epidemiology
Volume10
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Biological Products
Inflammatory Bowel Diseases
Crohn Disease
Cohort Studies
Ulcerative Colitis
Safety
Population
Steroids
Drug Utilization
Health Information Systems
Propensity Score
Drug Users
Italy
Prescriptions
Hospitalization
Tumor Necrosis Factor-alpha
Infliximab
Adalimumab
Therapeutics
Infection

Keywords

  • Biologics
  • Inflammatory bowel disease
  • Real-world effectiveness

ASJC Scopus subject areas

  • Epidemiology

Cite this

Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. / Di Domenicantonio, Riccardo; Trotta, Francesco; Cascini, Silvia; Agabiti, Nera; Kohn, Anna; Gasbarrini, Antonio; Davoli, Marina; Addis, Antonio.

In: Clinical Epidemiology, Vol. 10, 01.01.2018, p. 203-213.

Research output: Contribution to journalArticle

Di Domenicantonio, Riccardo ; Trotta, Francesco ; Cascini, Silvia ; Agabiti, Nera ; Kohn, Anna ; Gasbarrini, Antonio ; Davoli, Marina ; Addis, Antonio. / Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. In: Clinical Epidemiology. 2018 ; Vol. 10. pp. 203-213.
@article{e9a89310136e4f769d5ca37799b8b9de,
title = "Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease",
abstract = "Background: The comparison of effectiveness and safety of anti-tumor necrosis factor-alpha agents for the treatment of inflammatory bowel disease (IBD) is relevant for clinical practice and stakeholders. Objective: The objective of this study was to compare the risk of abdominal surgery, steroid utilization, and hospitalization for infection in Crohn’s disease (CD) or ulcerative colitis (UC) patients newly treated with infliximab (IFX) or adalimumab (ADA). Methods: A retrospective population-based cohort study was performed using health information systems data from Lazio region, Italy. Patients with CD or UC diagnosis were enrolled at first prescription of IFX or ADA during 2008–2014 (index date). Only new drug users were followed for 2 years from the index date. IFX versus ADA adjusted hazard ratios were calculated applying “intention-to-treat” approach, controlling for several characteristics and stratifying the analysis on steroid use according to previous drug utilization. Sensitivity analyses were performed according to “as-treated” approach, adjusting for propensity score, censoring at switching or discontinuation, and evaluating different lengths of follow-up periods. Results: We enrolled 1,432 IBD patients (42{\%} and 83{\%} exposed to IFX for CD and UC, respectively). In both diseases, treatment effects did not differ in any outcome considered, and sensitivity analyses confirmed the results from the main analysis. Conclusion: In our population-based cohort study, effectiveness and safety data in new users of ADA or IFX with CD or UC were comparable for the outcomes we tested.",
keywords = "Biologics, Inflammatory bowel disease, Real-world effectiveness",
author = "{Di Domenicantonio}, Riccardo and Francesco Trotta and Silvia Cascini and Nera Agabiti and Anna Kohn and Antonio Gasbarrini and Marina Davoli and Antonio Addis",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/CLEP.S150030",
language = "English",
volume = "10",
pages = "203--213",
journal = "Clinical Epidemiology",
issn = "1179-1349",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease

AU - Di Domenicantonio, Riccardo

AU - Trotta, Francesco

AU - Cascini, Silvia

AU - Agabiti, Nera

AU - Kohn, Anna

AU - Gasbarrini, Antonio

AU - Davoli, Marina

AU - Addis, Antonio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The comparison of effectiveness and safety of anti-tumor necrosis factor-alpha agents for the treatment of inflammatory bowel disease (IBD) is relevant for clinical practice and stakeholders. Objective: The objective of this study was to compare the risk of abdominal surgery, steroid utilization, and hospitalization for infection in Crohn’s disease (CD) or ulcerative colitis (UC) patients newly treated with infliximab (IFX) or adalimumab (ADA). Methods: A retrospective population-based cohort study was performed using health information systems data from Lazio region, Italy. Patients with CD or UC diagnosis were enrolled at first prescription of IFX or ADA during 2008–2014 (index date). Only new drug users were followed for 2 years from the index date. IFX versus ADA adjusted hazard ratios were calculated applying “intention-to-treat” approach, controlling for several characteristics and stratifying the analysis on steroid use according to previous drug utilization. Sensitivity analyses were performed according to “as-treated” approach, adjusting for propensity score, censoring at switching or discontinuation, and evaluating different lengths of follow-up periods. Results: We enrolled 1,432 IBD patients (42% and 83% exposed to IFX for CD and UC, respectively). In both diseases, treatment effects did not differ in any outcome considered, and sensitivity analyses confirmed the results from the main analysis. Conclusion: In our population-based cohort study, effectiveness and safety data in new users of ADA or IFX with CD or UC were comparable for the outcomes we tested.

AB - Background: The comparison of effectiveness and safety of anti-tumor necrosis factor-alpha agents for the treatment of inflammatory bowel disease (IBD) is relevant for clinical practice and stakeholders. Objective: The objective of this study was to compare the risk of abdominal surgery, steroid utilization, and hospitalization for infection in Crohn’s disease (CD) or ulcerative colitis (UC) patients newly treated with infliximab (IFX) or adalimumab (ADA). Methods: A retrospective population-based cohort study was performed using health information systems data from Lazio region, Italy. Patients with CD or UC diagnosis were enrolled at first prescription of IFX or ADA during 2008–2014 (index date). Only new drug users were followed for 2 years from the index date. IFX versus ADA adjusted hazard ratios were calculated applying “intention-to-treat” approach, controlling for several characteristics and stratifying the analysis on steroid use according to previous drug utilization. Sensitivity analyses were performed according to “as-treated” approach, adjusting for propensity score, censoring at switching or discontinuation, and evaluating different lengths of follow-up periods. Results: We enrolled 1,432 IBD patients (42% and 83% exposed to IFX for CD and UC, respectively). In both diseases, treatment effects did not differ in any outcome considered, and sensitivity analyses confirmed the results from the main analysis. Conclusion: In our population-based cohort study, effectiveness and safety data in new users of ADA or IFX with CD or UC were comparable for the outcomes we tested.

KW - Biologics

KW - Inflammatory bowel disease

KW - Real-world effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85041524437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041524437&partnerID=8YFLogxK

U2 - 10.2147/CLEP.S150030

DO - 10.2147/CLEP.S150030

M3 - Article

AN - SCOPUS:85041524437

VL - 10

SP - 203

EP - 213

JO - Clinical Epidemiology

JF - Clinical Epidemiology

SN - 1179-1349

ER -